GSK to Discontinue Flovent, Popular Asthma Inhaler

Generic versions to replace the branded product amid concerns over insurance coverage and potential hurdles for patients.

GSK, the manufacturer of Flovent, a popular asthma inhaler, has confirmed that it will discontinue the production of all strengths of both Flovent HFA and branded Flovent Diskus at the start of 2024.
The discontinued products will be replaced with generic versions that are nearly identical, containing the same medication in the same device with the same instructions.
Medical providers who prescribe Flovent express concern about potential hurdles for patients in getting the generic version covered by insurance.
GSK recommends patients refill their current Flovent prescriptions as soon as possible and discuss potential temporary substitutes with their medical providers.
The discontinuation of Flovent is linked to changes in Medicaid rebates that would result in penalties for GSK due to previous price increases.